ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Edwards Lifesciences Corp

Edwards Lifesciences Corp (EW)

90.90
2.06
(2.32%)
Closed June 22 4:00PM
90.90
0.00
(0.00%)
After Hours: 5:28PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
90.90
Bid
-
Ask
-
Volume
5,268,087
88.86 Day's Range 90.965
60.57 52 Week Range 96.12
Market Cap
Previous Close
88.84
Open
89.61
Last Trade
1599459
@
90.9
Last Trade Time
Financial Volume
$ 473,400,518
VWAP
89.8619
Average Volume (3m)
2,689,367
Shares Outstanding
602,600,000
Dividend Yield
-
PE Ratio
39.06
Earnings Per Share (EPS)
2.33
Revenue
6B
Net Profit
1.4B

About Edwards Lifesciences Corp

Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology serving patients in 100+ countries with the help of our employees ... Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology serving patients in 100+ countries with the help of our employees in areas including Clinical Affairs Quality Engineering Research & Development Regulatory Affairs Sales & Marketing corporate functions and more. Our roots date back to 1958 when Miles Lowell Edwards a retired engineer with a background in hydraulics and fuel pump operations set out to build the first artificial heart. Edwards believed the heart could be mechanized and was encouraged by Dr. Albert Starr to focus on developing an artificial heart valve. After just two years the first Starr-Edwards mitral valve was developed and successfully placed in a patient. This innovation spawned Edwards Laboratories. Show more

Sector
Ortho,prosth,surg Appl,suply
Industry
Ortho,prosth,surg Appl,suply
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Edwards Lifesciences Corp is listed in the Ortho,prosth,surg Appl,suply sector of the New York Stock Exchange with ticker EW. The last closing price for Edwards Lifesciences was $88.84. Over the last year, Edwards Lifesciences shares have traded in a share price range of $ 60.57 to $ 96.12.

Edwards Lifesciences currently has 602,600,000 shares outstanding. The market capitalization of Edwards Lifesciences is $54.78 billion. Edwards Lifesciences has a price to earnings ratio (PE ratio) of 39.06.

Edwards Lifesciences (EW) Options Flow Summary

Overall Flow

Bullish

Net Premium

197k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

EW Latest News

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a...

Edwards Lifesciences to Sell Critical Care to BD

Agreement strengthens Edwards’ strategy to advance structural heart innovation Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.43.8857142857187.590.96585.12319353088.2388214CS
43.243.6960985626387.6690.96585.12250884587.60841129CS
12-4.66-4.8765173712995.5695.7383.5268936788.34489362CS
2616.5322.226704316374.3796.1271.67336449785.73691577CS
52-0.62-0.67744755244891.5296.1260.57368811379.4110044CS
156-10.56-10.4080425784101.46131.7360.57322908988.63971025CS
260-102.66-53.0378177309193.56248.560.57274243799.0608345CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

EW Discussion

View Posts
weedtrader420 weedtrader420 2 years ago
WOOHOOOOOO EW$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
Weeeeeeeeeeeee
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
WOOHOOOOOO
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
EW$
πŸ‘οΈ0
weedtrader420 weedtrader420 2 years ago
Big move up EW WOOHOOOOOO
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 4 years ago
3:1 Split for EW on June 1st. Adjust your parameters.
πŸ‘οΈ0
Prominent Capital Prominent Capital 4 years ago
Have anyone see the earnings?
Is that true that beats estimations ??
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
$EW great article Edwards Lifesciences Corporation Nyse Ew Short Squeeze
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 5 years ago
Ugh. Off 5% on the day. (along with much of the health sector....)
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 5 years ago
EW up over 7% this AM with news out that Edwards and Boston Scientific have settled a patent dispute:
https://finance.yahoo.com/m/ed5c9955-43b5-3c4d-b71b-ac7ed1df50c4/edwards-lifesciences%27-stock.html
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 6 years ago
A 7+% gain on share price this AM. News says it might be an acquisition target.

https://www.barrons.com/articles/boston-scientific-edwards-lifesciences-may-tempt-j-j-1537575592?siteid=yhoof2&yptr=yahoo

It's trading well above its previous 52 week high.
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 6 years ago
Price/Share off 7% this AM.

Ouch!
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 6 years ago
It's been a while since I updated my EW position history. This histogram shows where it's been since the start in 2014 and updates what's happened since about a year ago:



I was lucky to cut overall risk exposure when I did as those funds were used to supplement other positions in a 10 stock portfolio. It's taken until just the last month or so for the stock to rise above that same price/share. Those opportunistic buys I made back under $100/share now look pretty good.

Value Line now gives EW a 3-5 year price target of between $160 and $245. It's still ranked A+ for financial strength with price growth persistence at 80 (5 to 100 range) and stock price stability of 45 (5 to 100 range).
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 7 years ago
Thanks. It will be fun to watch unfold and I have time to wait. Cash hasn't been earning anything for a very long time, so another price dip would make me smile. So would a price rise, but for a different reason.

The only time I'm not smiling is when the price/share goes flat!
πŸ‘οΈ0
Phaeton Phaeton 7 years ago
Nice reply and lets hope that Value Line is correct. that target is a nice one.
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 7 years ago
Hi P, Re: Long term with EW.............

2014 was when I first added EW to my portfolio at around $36 (split adjusted). So, it's done well for me. Last Sept I reduced my overall holding in EW by around 50% because of it becoming overweight in that 10 stock portf. That was at around $116/sh.

About a month later it dropped back to $93 and I added back some shares. It continued down and I managed to add more shares at around $85/share.


(Stacked Bar Histogram: Red on bottom is cash in reserve, Green is the stock value)

It's again starting to throw off some cash for me with a sale of 10% of the shares at around $110/sh. I need an additional +10% added to the price before I'll again take some off the table.

This week's newest EW report from Value Line has raised its "Timeliness" rank to 2 with a 3-5 year "appreciation potential" target of $150 to $220/share. It also remains on their "Highest Growth Stocks" list (Page 39 of the Summary and Index section). It carries a VL Financial Strength rank of A+ (second highest).

It has a "Price Growth Persistence" rank of 80 (5 to 100 range) but carries a "Stock Price Stability" rank of 35 (5 to 100 range). So, it would appear it has a long term upward trend with hick-ups along the way. I've been trading the hick-ups while enjoying the long term growth.

I, too, am surprised it doesn't have much following here.
πŸ‘οΈ0
Phaeton Phaeton 7 years ago
Can't wait to see where Edwards goes the next 12 months.
πŸ‘οΈ0
Phaeton Phaeton 7 years ago
Surprised nobody is watching Edwards on this site. I invested back in 2013 and only wished I was smart enough to have bought more in the last year. I see EW eventually back to the 120.00 area before the end of 2017.
πŸ‘οΈ0
ValueInvestor15 ValueInvestor15 7 years ago
5yr DCF imply Edwards Lifesciences $EW has 9% upside before earnings Wednesday:

DCF Analysis
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 8 years ago
Hi J99, Re: Drop in price...........

I sold some of my position at around $116, so couldn't resist adding about 12% more to the remaining share count this AM at 93.19. That's about a 20% discount from my latest sale.

Value Line dropped their "Timeliness" rank on the 14th of this month to "4" which is second lowest (looking out 12 months). Yesterday's selling binge was massive. So, since this is a long term holding, I'm happy to have the extra shares. It's nice to profitably trade around the core position.
πŸ‘οΈ0
jones99 jones99 8 years ago
Still think this is oversold. Best in class med device in a huge industry. Unfortunate drop on earnings that were in line.
πŸ‘οΈ0
Don Don 8 years ago
Saturday News....

http://www.prnewswire.com/news-releases/edwards-sapien-xt-valve-meets-primary-endpoint-in-partner-ii-trial-300245045.html
πŸ‘οΈ0
TREND1 TREND1 8 years ago
Inst % Owned = 95%
πŸ‘οΈ0
TREND1 TREND1 8 years ago
Float = 214.11M
πŸ‘οΈ0
TREND1 TREND1 8 years ago
EPS = 2.30
πŸ‘οΈ0
TREND1 TREND1 8 years ago
EW DAY

πŸ‘οΈ0
TREND1 TREND1 8 years ago
SEE MY POSTS AT


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121003349





EW is 1 of 2
I am following starting today.
πŸ‘οΈ0
Phaeton Phaeton 10 years ago
Anybody following EW? Where are we heading now that the big lawsuit is settled. Seems to be a good settlement for EW and with some nice future royalties.
πŸ‘οΈ0
robtewms robtewms 10 years ago
I'm out of this one for now. Glad you are enjoying the PPS jump. I haven't decided whether or when to re- enter. Good luck to you.
πŸ‘οΈ0
Belek Belek 10 years ago
fantastic move this morning..........

best, jeff
πŸ‘οΈ0
Belek Belek 10 years ago
not sure about that, EW has a 50/200ema crossover approaching, if it

breaks up thru $73 and closes above, my guess EW can almost run to $100

by this summer, I'll wait till the chart tells me otherwise...................good luck
πŸ‘οΈ0
robtewms robtewms 10 years ago
Thanks for sharing. In the past, outperform is code for you should have taken some profits, the price of this stock is getting ready to drop.
πŸ‘οΈ0
Belek Belek 10 years ago
Edwards Life Sciences u[graded this morning to Outperform by Wells Fargo

no price target but i notice a lot of insider sells lately from option exercise....
πŸ‘οΈ0
robtewms robtewms 10 years ago
Thanks for sentiment. I like this company, but I just sold all of my shares yesterday. I'm not sure why a company with such great products doesn't translate into superior stock performance. I'm out for now. I may come back in at a lower price. I made a few bucks after being under water for too long. Got out while gettin' was good. GLTA.
πŸ‘οΈ0
Belek Belek 10 years ago
looks like EW on a upward trajectory for now, maybe get to $100

πŸ‘οΈ0
RealGenius RealGenius 10 years ago
Boom! Medtronic Corevalve early approval granted by the FDA. See ya Edwards.
πŸ‘οΈ0
robtewms robtewms 11 years ago
This stock has been doing well in my portfolio. But, i don't see many new posts to this board. What is going on here?
πŸ‘οΈ0
robtewms robtewms 11 years ago
Can you point out the interesting parts for you? I tried to find something interesting but found that I was more distracted by the CFO's ramblings than anything else.
πŸ‘οΈ0
ECole ECole 11 years ago
Goldman-Sachs Global-Healthcare-Conference

Interesting comments made by EW

read here
πŸ‘οΈ0
robtewms robtewms 11 years ago
I'm a new investor. What happened with knock-off?
πŸ‘οΈ0
Texstar Texstar 11 years ago
Look at ICU Medicals FloTrac knockoff. This could hurt
πŸ‘οΈ0
THESTCOKHUNTER THESTCOKHUNTER 12 years ago
TAVI: Mixed results for Edwards' Sapien valve in latest Partner analysis

https://www.massdevice.com/news/tavi-mixed-results-edwards-sapien-valve-latest-partner-analysis

πŸ‘οΈ0
THESTCOKHUNTER THESTCOKHUNTER 12 years ago
Edwards Lifesciences (NYSE:EW) reported EPS of $0.58 in the third quarter of 2012, surpassing the Zacks Consensus Estimate by $0.02. Sales increased 8.5% to $447.9 million, in line with the preliminary result but lagged the original guidance of $465-$485 million. This was primarily due to lower-than-expected THV sales due to economic uncertainties in Europe, coverage issues for certain inoperable patients in US and later-than expected approval of Sapien in high-risk patients.

Given these headwinds, the company lowered its outlook for 2012. We prefer to avoid the stock and accordingly downgrade it to Underperform.

Edwards current trailing 12-month earnings multiple is 36.3. The stock is currently trading at 27.1x the 2013 EPS estimate of $3.21. Our target price is based on 24.6x our 2013 EPS estimate.

πŸ‘οΈ0
THESTCOKHUNTER THESTCOKHUNTER 12 years ago
there is interest,we just keep to ourselves, ihub message boards

for penny fluffers.....................

best
πŸ‘οΈ0
THESTCOKHUNTER THESTCOKHUNTER 12 years ago
well, time to buy EW???????????

πŸ‘οΈ0
m177 m177 12 years ago
EW, another guidance hit

Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."

πŸ‘οΈ0
dfeickeesq dfeickeesq 12 years ago
I can't understand why there is no interest in this stock, I have made a great deal of money on this investment. Cutting edge and FDA approval. It will split again.
πŸ‘οΈ0
dfeickeesq dfeickeesq 12 years ago
I believe that this is a likely split candidate once again. Watch the movement here shortly.
πŸ‘οΈ0
DrMG DrMG 12 years ago
I purchase this one on the low point, it make good up and down movement.
πŸ‘οΈ0
timvic timvic 12 years ago
EW-stock analysis
EW gained 0.76% on 02/10/12.
EW is trading in the range of $69.81 - $83.96 in the past 30 days.
Commodity Channel Index (CCI) is bullish for EW.
EW formed a Bullish Macd Crossover signal.
Money Flow Index (MFI) is bearish and moving down for EW.
The 10-day simple moving average is bearish and moving down for EW.
Average volume decrease over 5% for EW.
Stock performance base on day of week in the past 90 days.
Monday: 12.48%
Tuesday: 7.46%
Wednesday: 0.61%
Thursday: -1.30%
Friday: -12.32%
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock